search
Back to results

Efficacy of the Early Prone-positioning in Hospitalized Patients With Mild Covid-19 Pneumonia (EpCOT)

Primary Purpose

COVID-19 Pneumonia

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
prone positioning
Sponsored by
University of Milano Bicocca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for COVID-19 Pneumonia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • > 18 years
  • positive PCR for Sars-Cov-2 Rna on any respiratory samples within 7 days from enrollment
  • imaging positive for pulmonary involvement or clinical evidence of respiratory involvement ( new onest of hypoxemia with 02 <80mmHg or SpO2 < 94% in air or need for oxygen therapy in oreder to mantaine SpO2 > 93%.
  • need of hospitalization

Exclusion Criteria:

  • start of prone-positioning cycles before being enrolled in the study
  • SpO2/FiO2 <200
  • need of high-flow oxygen therapy (HFNC) or need of non-invasive ventilation and/or CPAP or indications for intubation and mechanical ventilation
  • relative or absolute contraindications for prone positioning (eg facial fractures, advanced pregnancy, mental status alterations, spinal instability...)

Sites / Locations

  • Asst-Monza Ospedale San Gerardo

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Standard of care + prone positioning

Standard of care

Arm Description

Standard of care. Prone-positioning cycles as the following: 3-6 hours of prone-positioning twice a day.

Standard of care

Outcomes

Primary Outcome Measures

Accomplishment of the end-points
the occurence of the first of the following end-points: death, start of high flow oxygen therapy, CPAP, meccanichal ventilation, P/F <200

Secondary Outcome Measures

time of recovery
time of weaning from oxygen
variation of the clinical condition
mortality
number of adverse event
number and duration of prone positioning cycles

Full Information

First Posted
August 16, 2021
Last Updated
October 31, 2022
Sponsor
University of Milano Bicocca
search

1. Study Identification

Unique Protocol Identification Number
NCT05008380
Brief Title
Efficacy of the Early Prone-positioning in Hospitalized Patients With Mild Covid-19 Pneumonia
Acronym
EpCOT
Official Title
Open-label, Controlled, Randomized Clinical Trial on the Efficacy of Early Prone-positioning in Patients With Mild Pneumonia Due to SARS-CoV-2
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
August 16, 2021 (Actual)
Primary Completion Date
August 3, 2022 (Actual)
Study Completion Date
August 3, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Milano Bicocca

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The study aims to evaluate if the early prone-positioning in awake patients with mild Covid-19 pneumonia can reduce the need of high-flow oxygen-therapy, invasive or non-invasive ventilation and prevent the worsening of clinical conditions. Patients will be randomized on a 1:1 ratio and stratified based on the onset of symptoms (<10 days; >10 days) and need of oxygen therapy (no need; need). One branch of patients (interventional) will undergo standard of care treatment + prone-positioning cycles, the other one (controll) will undergo standard of care treatment alone. Patients will be evaluated evaluated on the day of the enrolment, on day 1, day 3, day 7 and every 7 days until the patient dismissal or until day 28 (whichever occurs first). Adverse events and concurrent medications will be noted as well. The analysis will be conducted according to "intention to treat" criteria; primary outcomes will be calculated using survival-based methods.
Detailed Description
In this prospective, unicentred, open, controlled study, patients will be randomized on a 1:1 ratio using casual permutation blocks, identifying two branches of treatment: standard of care; standard of care + prone positioning. Patients will be stratified in 4 strata based on the onset of symptoms (<10 days; >10 days) and need of oxygen therapy (no need; need). In order to obtain statistical significance, the sample size will include 96 patients. Patients in the SOC + prone-positioning branch will undergo cycles of prone-positioning following this scheme: 3-6 hours of prone-positioning twice a day. The actual length of the cycles will be registered during the study. Data will be collected using a dedicated CRF, which will include recording of adverse events and concurrent medications. Patients will be evaluated on the day of the enrolment, on day 1, day 3, day 7 and every 7 days until the patient dismissal or until day 28 (whichever occurs first). If dismissal occurs before day 28, a follow-up interview will be conducted in presence or on the phone to collect the remaining data. The analysis will be conducted according to "intention to treat" criteria; primary outcomes will be calculated using survival-based methods (Kaplan-Meier curves with log-rank test and Cox regression), while secondary outcomes will be evaluated using both survival-based methods and proportional odds model. The occurrence of adverse events and the causes of withdrawal from the study in the two branches of treatment will be compared using chi-square test.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19 Pneumonia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
96 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard of care + prone positioning
Arm Type
Experimental
Arm Description
Standard of care. Prone-positioning cycles as the following: 3-6 hours of prone-positioning twice a day.
Arm Title
Standard of care
Arm Type
No Intervention
Arm Description
Standard of care
Intervention Type
Procedure
Intervention Name(s)
prone positioning
Intervention Description
3-6 hours of prone-positioning twice a day
Primary Outcome Measure Information:
Title
Accomplishment of the end-points
Description
the occurence of the first of the following end-points: death, start of high flow oxygen therapy, CPAP, meccanichal ventilation, P/F <200
Time Frame
0-28 days
Secondary Outcome Measure Information:
Title
time of recovery
Time Frame
0-28 days
Title
time of weaning from oxygen
Time Frame
0-28 days
Title
variation of the clinical condition
Time Frame
0-28 days
Title
mortality
Time Frame
0-28 days
Title
number of adverse event
Time Frame
0-28 days
Title
number and duration of prone positioning cycles
Time Frame
0-28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: > 18 years positive PCR for Sars-Cov-2 Rna on any respiratory samples within 7 days from enrollment imaging positive for pulmonary involvement or clinical evidence of respiratory involvement ( new onest of hypoxemia with 02 <80mmHg or SpO2 < 94% in air or need for oxygen therapy in oreder to mantaine SpO2 > 93%. need of hospitalization Exclusion Criteria: start of prone-positioning cycles before being enrolled in the study SpO2/FiO2 <200 need of high-flow oxygen therapy (HFNC) or need of non-invasive ventilation and/or CPAP or indications for intubation and mechanical ventilation relative or absolute contraindications for prone positioning (eg facial fractures, advanced pregnancy, mental status alterations, spinal instability...)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paolo Bonfanti
Organizational Affiliation
asst-monza Ospedale San Gerardo
Official's Role
Principal Investigator
Facility Information:
Facility Name
Asst-Monza Ospedale San Gerardo
City
Monza
State/Province
Lombardia
ZIP/Postal Code
20900
Country
Italy

12. IPD Sharing Statement

Learn more about this trial

Efficacy of the Early Prone-positioning in Hospitalized Patients With Mild Covid-19 Pneumonia

We'll reach out to this number within 24 hrs